Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life Sciences Partners (LSP) and Bristol-Myers Squibb have collaborated to find out European breakthrough technologies and products in immuno-oncology and other areas.
Subscribe to our email newsletter
Bristol-Myers Squibb has invested an undisclosed amount in LSP 5, the latest LSP fund.
It is the first investment by the company in a European healthcare fund. A representative of Bristol-Myers Squibb will join the LSP 5 advisory board.
Bristol-Myers Squibb senior vice president of business development Paul Biondi said: "Bristol-Myers Squibb is committed to working closely with the venture community to identify and invest in innovative science that has the potential to bring forward transformational medicines to patients with unmet need."
Apart from immuno-oncology, Bristol-Myers Squibb is also undertaking potential treatment options in other areas of significant unmet need, including cardiovascular diseases like heart failure and thrombosis, various genetically defined diseases, fibrosis and immunoscience.
LSP general partner Joachim Rothe said: "LSP is committed to seeking, nurturing and growing healthcare investment opportunities which have the potential to have a positive impact on society.
"We are very proud to be chosen by Bristol-Myers Squibb as a partner for investing in European innovation, which is validation of LSP´s influential role as a long-standing specialist European life science investor."